Abstract: The invention described herein relates to new combretastatin derivatives obtained by total synthesis and having the following general formula: in which the groups are as defined in the description here below. Said compounds, though chemically related to the structure of cis/trans-combretastatin, do not always bind tubulin, but nevertheless exhibit cytotoxic activity of interest in the oncological field as anticancer and/or antiangiogenic agents.

Abstract: Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives exhibit antiangiogenic activity and are devoid of anticoagulant activity.

Abstract: Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and R1 groups have the meanings indicated in the description. Said glycosaminoglycan derivatives are endowed with antiangiogenic and heparanase-inhibiting activity ans are devoid of anticoagulant activity.

Abstract: Compounds of formula useful for treating tumors, particularly mammary carcinoma and colon carcinoma.

Abstract: A memory, particularly but not limitatively a flash memory, comprises at least one data storage area comprising a plurality of data storage locations, and an access circuitry for accessing the data storage locations for either retrieving or altering a data content thereof, depending for example on a memory user request. The memory includes at least one first user-configurable flag element and a second user-configurable flag element. Both the at least one first and the second flag elements are used by a user to set a protected state of the respective data storage area against alteration of the content of the data storage locations thereof. The protected state defined by setting the first flag element is user-removable, i.e., it can be removed by request from the user, so as to enable again the alteration of the content of the data storage area.

Abstract: Bis-heterocyclic compounds of general formula (1) are described which are useful as antitumour and cheomsensitising agents.

Abstract: Compounds of formula (I) where n is the number 0, 1 or 2, processes for the preparation together with methods for treating pathologies related to an altered &agr;v&bgr;3 integrin-mediated cell attachment, in particular where inhibition of angiogenesis is desired, for example in tumors, also associated with metastasis.

Abstract: The present invention discloses compounds of formula (I) wherein n is the number 0, 1 or 2. There are also disclosed processes for the preparation of the compounds, together with methods for treating pathologies related to an altered &agr;v&bgr;3 integrin-mediated cell attachment, in particular wherein the inhibition of angiogenesis is desired, for example in tumors, also associated with metastasis.

Abstract: The present invention discloses compounds of formula (I) 1

Abstract: A method of protecting data in a semiconductor electronic memory, which includes using a protected memory portion within the matrix and respective dedicated decoding portions for storing, into the protected portion, a protection code without the address area of the matrix. The protection code can only be written and/or read through a command interpreter.

Abstract: The present invention discloses compounds of formula (I) wherein n is the number 0, 1 or 2. There are also disclosed processes for the preparation of said compounds, together with methods for treating pathologies related to an altered &agr;v&bgr;3 integrin-mediated cell attachment, in particular wherein the inhibition of angiogenesis is desired, for example in tumors, also associated with metastasis.

Abstract: The present invention discloses compounds of formula (I) 1

Abstract: The present invention refers to conjugates formed by a natural or modified oligonucleotide, capable of forming a triple helix with a DNA chain, linked to the aglycone moiety of an anthracycline or to an anthracyclinone via an appropriated linker; such conjugates are capable to bind selectively to specific DNA regions inhibiting their transcription and therefore the formation of the corresponding codified protein.

Abstract: 8-fluoro-anthracyclines of formula (I) have anti-tumor activity. ##STR1## wherein: R is chosen in the group consisting of H, OH, OR.sub.4 wherein R.sub.4 is chosen in the group consisting of CHO, COCH.sub.3, acyl derivative of a carboxylic acid containing up to 6 carbon atoms;R.sub.1 is chosen in the group consisting of: H, OH, OCH.sub.3 ;R.sub.2 is chosen in the group consisting of: H, OH, NH.sub.2R.sub.3 is chosen in the group consisting of: H, OH, NH.sub.2, residue of formula (A) ##STR2## The compounds are characterized by having cis-stereochemistry between the groups 8--F and 9--OH. Their preparation and pharmaceutical compositions containing them are also described.

Abstract: This invention relates to polyaminopyrrolecarboxyamide derivatives of general formula (I) and their pharmaceutically acceptable salts, in which A represents a chemical bond or an aromatic or heteroaromatic radical, and:if A is a chemical bond, R is hydrogen, alkyl, dialkylaminoalkyl, alkenyl, cycloalkyl, arylalkyl, arylalkenyl, haloalkyl, or an aromatic or heteroaromatic radical;whereas if A is an aromatic or heteroaromatic radical, R is nitro, amino or formylamino;n is 0 or a whole number between 1 and 4;Z is an alkylene or aromatic radical.